Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose escalation study of teclistamab in relapsed or refractory multiple myeloma
2023-503438-40-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, open-label trial of teclistamab in multiple myeloma (MM) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting toxicities in Part 1, Safety and tolerability in Part 2 and 1 more. Planned start Jul 2024; status: authorised.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-503438-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503438-40-00.